Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial)

Ramy Rahme (1) , Lionel Ades (1) , Xavier Thomas (2) , Agnes Guerci-Bresler (3) , Arnaud Pigneux (4) , Norbert Vey (5) , Emmanuel Raffoux (1) , Sylvie Castaigne (6) , Olivier Spertini (7) , Sebastian Wittnebel (8) , Jean Pierre Marolleau (9) , Gandhi Damaj (10) , Dominique Bordessoule (11) , Julie Lejeune (12) , Sylvie Chevret (13) , Pierre Fenaux (1)

1 AP-HP - Hopital Saint-Louis [AP-HP]
2 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
3 Service d'Hématologie [CHRU Nancy]
4 CHU Bordeaux [Bordeaux]
5 Institut Paoli-Calmettes
6 CHV - Centre Hospitalier de Versailles André Mignot
7 UNIL - Université de Lausanne = University of Lausanne
8 Institut Jules Bordet [Bruxelles]
9 CHU Amiens-Picardie
10 Laboratoire d'Hématologie Biologique [CHU Caen]
11 Service d'Hématologie biologique [CHU Limoges]
12 Service de biostatistiques et information médicale [Saint-Louis]
13 Service de biostatistiques et information médicale [Saint-Louis]

No abstract available

Domaines: Sciences du Vivant [q-bio]

Ramy Rahme, Lionel Ades, Xavier Thomas, Agnes Guerci-Bresler, Arnaud Pigneux, et al.. Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial). Haematologica, 2018, 103 (11), pp.E519-E521. ⟨10.3324/haematol.2018.193151⟩. ⟨hal-03605023⟩